Germline Testing Finds More Variants in Selected Lung Cancer Patients
A systematic review of 49 studies compares pathogenic variant prevalence between selected and unselected lung cancer patients.
Updated on Nov. 3, 2026 in Cancer
Live Poll
Should doctors test all lung cancer patients for inherited gene mutations, or only some?
A systematic review published in the journal Lung Cancer found that germline testing detects more pathogenic variants in patients selected for testing based on clinical criteria than in unselected patients. The review analyzed 49 eligible studies.
Why it matters
Lung cancer has a lower baseline prevalence of pathogenic germline variants than some other cancers, which has fueled debate over whether broad, unselected testing is worthwhile. The findings point to patient selection as a central factor in determining testing yield.
The review's evidence is a descriptive synthesis of 49 studies, showing a median variant prevalence of about 6% in unselected lung cancer cohorts versus about 27% in clinically selected cohorts. Formal comparative statistical testing was not performed, and family history was rarely used as a selection criterion.
The details
Researchers categorized the 49 studies by how patients were chosen for testing, with 21 studies testing unselected lung cancer populations and 18 applying some form of selection beforehand. Ten studies tested across multiple cancer types, and the synthesis was descriptive rather than statistical.
Timeline
The systematic review was published in the journal Lung Cancer in 2026, volume 219.
Big Picture
The review adds quantitative evidence to the long-running debate over whether broad germline testing is justified in lung cancer, where baseline variant prevalence is lower than in breast and ovarian cancers. It suggests that clinical selection, rather than universal testing, may drive meaningful yield.
For patients with lung cancer, the findings suggest that clinical criteria and family history may help determine whether germline testing is likely to uncover actionable variants. Patients may wish to discuss with their oncology team whether testing is appropriate for their individual situation.
The takeaway
Patient selection appears to matter as much as the disease itself when deciding whether germline testing will yield results. Readers facing a lung cancer diagnosis can ask their care team whether their clinical history or family background warrants testing.
Further reading
Explore more on Cancer research and treatment developments.
Live Poll
Should doctors test all lung cancer patients for inherited gene mutations, or only some?
